New study seeks right dose for cancer drug in patients with liver issues
NCT ID NCT04617522
First seen Feb 17, 2026 · Last updated May 14, 2026 · Updated 15 times
Summary
This early-phase study aims to find a safe starting dose of the drug sacituzumab govitecan for people with advanced solid tumors who also have moderate liver impairment. About 30 participants will receive the drug to monitor side effects and how the drug moves through the body. The goal is to help doctors give the right dose to this specific group of patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER FAILURE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centre Leon Berard
RECRUITINGLyon, 69373, France
-
Christiana Care Health Services
RECRUITINGNewark, Delaware, 19713, United States
-
Hospital Universitario Virgen del Rocío
RECRUITINGSeville, 41013, Spain
-
Institut Bergonie Medical Oncology
RECRUITINGBordeaux, 33000, France
-
Institut Català d'Oncologia - L'Hospitalet de Llobregat
RECRUITINGBarcelona, 08908, Spain
-
Institut de Cancerologie de l'Ouest (ICO) - Saint-Herblain
RECRUITINGSaint-Herblain, France
-
NEXT Austin
WITHDRAWNAustin, Texas, 78758, United States
-
NEXT Oncology
RECRUITINGSan Antonio, Texas, 78229, United States
-
Oncology Consultants, P.A.
RECRUITINGHouston, Texas, 77030, United States
-
Pacific Shores Medical Group
SUSPENDEDLong Beach, California, 90813, United States
-
Texas Liver Institute
RECRUITINGSan Antonio, Texas, 78215, United States
-
The University of Texas M.D. Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
University of Maryland
RECRUITINGBaltimore, Maryland, 21201, United States
Conditions
Explore the condition pages connected to this study.